Advertisement

ADVERTISEMENT

Jordan Kadish

News
Sorafenib Maintenance Post-AlloHSCT Significantly Improves Survival, Reduces Relapse Rate Among Patients With FLT3-ITD-Mutated AML
10/03/2023
An updated post-hoc analysis from a phase 3 trial found sorafenib maintenance after hematopoietic stem-cell transplantation significantly improved long-term survival and reduced relapse rate among patients with FLT3-ITD-mutated AML undergoing...
An updated post-hoc analysis from a phase 3 trial found sorafenib maintenance after hematopoietic stem-cell transplantation significantly improved long-term survival and reduced relapse rate among patients with FLT3-ITD-mutated AML undergoing...
An updated post-hoc analysis...
10/03/2023
Oncology
News
Inflammatory Comorbidities as Prognostic Factors Among Younger Patients With Myelofibrosis
01/05/2024
Retrospective analysis findings indicated that inflammatory comorbidities were correlated with progression of disease risk among younger patients with myelofibrosis.
Retrospective analysis findings indicated that inflammatory comorbidities were correlated with progression of disease risk among younger patients with myelofibrosis.
Retrospective analysis findings...
01/05/2024
Oncology
News
No Association Observed Between Biosimilar Rituximab Exposure and Hypersensitivity Hospitalization
05/12/2023
According to findings from a 2-cohort study, exposure to biosimilar rituximab at initiation, switch, or over time was not associated with hospitalization due to hypersensitivity, compared to originator rituximab.
According to findings from a 2-cohort study, exposure to biosimilar rituximab at initiation, switch, or over time was not associated with hospitalization due to hypersensitivity, compared to originator rituximab.
According to findings from a...
05/12/2023
Oncology
News
Daratumumab Plus Lenalidomide and Dexamethasone Among Patients With R/R MM
03/27/2023
According to a phase 3 study, daratumumab plus lenalidomide and dexamethasone treatment resulted in improved overall survival among patients with relapsed/refractory multiple myeloma, compared to lenalidomide and dexamethasone alone.
According to a phase 3 study, daratumumab plus lenalidomide and dexamethasone treatment resulted in improved overall survival among patients with relapsed/refractory multiple myeloma, compared to lenalidomide and dexamethasone alone.
According to a phase 3 study,...
03/27/2023
Oncology
News
Parsaclisib Plus Obinutuzumab and Bendamustine Demonstrates Preliminary Efficacy, Safety for Patients With R/R Follicular Lymphoma
07/31/2023
The combination of parsaclisib plus obinutuzumab and bendamustine demonstrated promising preliminary efficacy and safety among patients with R/R follicular lymphoma.
The combination of parsaclisib plus obinutuzumab and bendamustine demonstrated promising preliminary efficacy and safety among patients with R/R follicular lymphoma.
The combination of parsaclisib...
07/31/2023
Oncology
News
Mosunetuzumab Monotherapy Yields Notable Efficacy, Manageable Safety for R/R DLBCL, Including for Patients With Prior CAR T-Cell Therapy
09/26/2023
Mosunetuzumab monotherapy demonstrated strong efficacy and a manageable safety profile among patients with relapsed/refractory diffuse large B-cell lymphoma, including those previously treated with CAR T-cell therapy.
Mosunetuzumab monotherapy demonstrated strong efficacy and a manageable safety profile among patients with relapsed/refractory diffuse large B-cell lymphoma, including those previously treated with CAR T-cell therapy.
Mosunetuzumab monotherapy...
09/26/2023
Oncology
News
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin, and Blinatumomab Shows Safety, Efficacy Among Patients With Philadelphia Chromosome-Negative B-Cell ALL
02/13/2024
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD,...
02/13/2024
Oncology
Conference Coverage
Neoadjuvant Chemotherapy Plus Radical Cystectomy Superior to Trimodality Therapy for Early-Stage Small Cell Bladder Cancer
02/22/2023
According to results presented at the 2023 ASCO GU Cancers Symposium, neoadjuvant chemotherapy plus radical cystectomy improved overall survival rates among patients with early-stage small cell bladder cancer compared to trimodality therapy.
According to results presented at the 2023 ASCO GU Cancers Symposium, neoadjuvant chemotherapy plus radical cystectomy improved overall survival rates among patients with early-stage small cell bladder cancer compared to trimodality therapy.
According to results presented...
02/22/2023
Oncology
News
Sutimlimab Among Patients With Chronic/Refractory Immune Thrombocytopenia
05/18/2023
According to findings from a phase 1 trial, sutimlimab treatment improved platelet counts and had a manageable safety profile among patients with chronic/refractory immune thrombocytopenia.
According to findings from a phase 1 trial, sutimlimab treatment improved platelet counts and had a manageable safety profile among patients with chronic/refractory immune thrombocytopenia.
According to findings from a...
05/18/2023
Oncology
News
BTK Inhibitor Acalabrutinib With or Without Obinutuzumab Demonstrated Improved Quality-Adjusted Survival Time Among Patients With Treatment-Naive CLL
06/06/2023
A phase 3 trial indicated that acalabrutinib with or without obinutuzumab resulted in improved quality-adjusted time without symptoms and toxicity vs chlorambucil plus obinutuzumab for patients with previously untreated CLL.
A phase 3 trial indicated that acalabrutinib with or without obinutuzumab resulted in improved quality-adjusted time without symptoms and toxicity vs chlorambucil plus obinutuzumab for patients with previously untreated CLL.
A phase 3 trial indicated that...
06/06/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD logo
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use